Danske Bank A S Makes New $14.35 Million Investment in Elanco Animal Health Incorporated $ELAN

Key Points

• Danske Bank acquired 583,026 Elanco Animal Health shares worth approximately $14.35 million during the second quarter, giving it a 0.12% stake. Institutional investors collectively own 97.48% of the company.
• Elanco reported quarterly earnings of $0.34 per share, beating estimates of $0.27, while revenue rose 10.2% year over year to $1.37 billion. The company guided for full-year 2026 earnings of $1.10–$1.16 per share.
• Insiders have been buying shares, including the CFO’s 4,200-share purchase and a director’s 10,000-share purchase. Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $29.09 versus a recent price of $23.47.

Danske Bank A S purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 583,026 shares of the company's stock, valued at approximately $14,348,000. Danske Bank A S owned approximately 0.12% of Elanco Animal Health at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ELAN. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after acquiring an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health during the second quarter worth $38,000. Root Financial Partners LLC grew its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health in the fourth quarter valued at $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health during the 4th quarter worth $46,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Insider Transactions at Elanco Animal Health

In other news, CFO Robert M. Vanhimbergen purchased 4,200 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $23.08 per share, with a total value of $96,936.00. Following the purchase, the chief financial officer owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Herendeen purchased 10,000 shares of the business's stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director owned 111,687 shares of the company's stock, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 23,198 shares of company stock valued at $537,109 in the last 90 days. Corporate insiders own 1.14% of the company's stock.

Elanco Animal Health Trading Down 4.2%

NYSE:ELAN opened at $23.47 on Friday. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $11.73 billion, a price-to-earnings ratio of -57.24, a PEG ratio of 1.47 and a beta of 1.67. The firm has a fifty day simple moving average of $24.56 and a two-hundred day simple moving average of $24.01.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ELAN. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen increased their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. Citigroup raised their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 22nd. Finally, UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source